Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Octreotide controlled release - Camurus

X
Drug Profile

Octreotide controlled release - Camurus

Alternative Names: CAM-2029; OclaizTM; Octreotide chloride controlled release; Octreotide subcutaneous (SC) depot - Camurus

Latest Information Update: 19 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Camurus
  • Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
  • Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycystic liver disease; Acromegaly
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Acromegaly
  • Phase III Neuroendocrine tumours
  • Phase II/III Polycystic liver disease
  • Phase II Adult respiratory distress syndrome

Most Recent Events

  • 21 Dec 2023 Preregistration for Acromegaly in USA (SC)
  • 21 Dec 2023 Pooled efficacy data from the phase III ACROINNOVA 1 and ACROINNOVA 2 trials in Acromegaly released by Camurus
  • 17 Jul 2023 Safety and efficacy data from a phase III ACROINNOVA 2 trial in Acromegaly released by Camurus
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top